Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Fig. 7

(Abstract O8). We further addressed the synergistic effect of CuraB-10 therapy with FDA approved checkpoint blockade therapy using the clinically relevant TRAMP/MIC spontaneous prostate tumor mouse model. Two points: 1) a percentage of TRAMP/MIC mice do not respond to checkpoint (CTLA4 or PD-1) blockade therapy, whereas all TRAMP/MIC mice are responsive to CuraB-10 therapy; also, a population of TRAMP/MICB animals died at 3-4 weeks of CTLA4 Rx alone. 2) CuraB-10 synergizes with checkpoint blockade (CTLA4 or PD-1) therapy when used in combination

Back to article page